The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.
The user is confused about the pricing and concentration of pyrilutamide powder for hair loss treatment. They calculate that 500mg of pyrilutamide can make ten 1ml applications of a 5% solution, costing $119.
The user switched from Finasteride to topical Dutasteride, Pyrilutamide, and Minoxidil due to hair loss, then decided to switch to oral Dutasteride because of pregnancy concerns. They are considering the frequency of oral Dutasteride use, with suggestions of using it a few times a week for better results and fewer side effects.
A user is seeking an online prescription for finasteride after local dermatologists recommended alternatives like vitamins, caffeinated shampoo, and minoxidil. Another user suggests using Mobidoctor to obtain the prescription.
Pyrilutamide (KX-826) is discussed as an anti-androgen treatment for hair loss, with mixed user experiences. Some users report no results, while others find it mildly effective.
User experienced slow gains with topical fin+min, switched to topical dut+min, and considered adding Eucapil. Another user suggested DUT may be less effective topically due to high molar mass and mentioned Fluridil as a weak anti-androgen that could help.
The user is struggling to obtain a finasteride prescription in France after moving there, despite previously using it alongside minoxidil, kz shampoo, and biotin supplements. They are advised to seek alternative doctors, consider telemedicine platforms, or explore topical finasteride options.
Dutasteride treatment may decrease sperm concentration, but levels remain above WHO recommendations and recover after discontinuation. The study has limitations, including small sample size and lack of pre-treatment sperm data, and does not assess other fertility factors.
User taking 1mg finasteride daily for 2 years, wants to block more scalp DHT. Seeks reference for additional topical DHT blockers like alfatradiol and fluridil.
Exploring potential treatments for hair loss, with the focus being on comparing RU58841 and Pyrilutamide. Finasteride, Dutasteride, oral Minoxidil, microneedling, topical Minoxidil, Biotin, Zinc, Vitamin D and Nizoral are also discussed as part of a treatment stack.
PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.
A user shared their positive experience with the telehealth service DocBright, highlighting its affordability and effectiveness in prescribing finasteride, oral minoxidil, and ketoconazole. They noted the service's unique ability to provide a prescription at age 17 but criticized the unprofessional communication with the dermatologist.
The user is experiencing significant hair shedding after 3 months of dutasteride mesotherapy, 2.5 months of Minoxidil, and using ketoconazole shampoo. They are concerned about the shedding but plan to continue the treatment.
Belgium disagrees with the EMA and does not authorize the 1 mg oral form of finasteride for androgenic alopecia, citing a negative benefit-risk ratio. Despite this, some individuals in Belgium can still obtain finasteride through prescriptions, and there is debate over its mental health risks versus its benefits for hair loss and other health issues.
The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.
Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.
Breezula (clascoterone) and Formula 82F (topical finasteride) are treatments for hair loss that block DHT differently; Breezula competes with DHT at the hormone receptor site without systemic effects, while 82F inhibits the enzyme that converts testosterone to DHT. Breezula may work for those who don't respond to finasteride and vice versa.
Nizoral is a suitable replacement for Ketoconazole, but ensure it contains 2% Ketoconazole. The yellow bottle is recommended and should last 3-4 months if used twice a week.
The conversation discusses hair loss treatments, specifically mentioning pyrilutamide, minoxidil, and finasteride. The consensus suggests starting treatment early, with finasteride being a preferred option.
The user started using a hair loss treatment called pyrilutamide and experienced mild chest discomfort and tightness, similar to previous side effects from RU58841. They plan to reduce the dosage due to these side effects and will provide an update on the results in 1-2 months.
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.
The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.
User experienced severe brain fog and anxiety from oral dutasteride and is considering dutasteride injections with PRP for hair loss, while currently using finasteride and oral minoxidil. They seek others' experiences with dutasteride mesotherapy and its side effects.
Topilutamide is a potential hair loss treatment between Clascoterone and RU58841. Users discuss finding Topilutamide powder and its possible benefits for those who can't afford or tolerate other treatments.
A user beginning to take Pyrilutamide as a treatment for their hair loss, and other users sharing their experiences with the drug or similar treatments such as Minoxidil, Finasteride, and RU58841.
User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.
Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.